Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Treating patients with multiple myeloma in Ireland

Philip Murphy • 1 Sep 2022
Multiple Myeloma Belantamab mafodotin Daratumumab Selinexor

Philip Murphy, MD, Beaumont Hospital, Dublin, Ireland, highlights the advances in treatment for multiple myeloma in recent years and the current treatment landscape for patients in Ireland who are newly diagnosed and those with relapsed/refractory (R/R) disease. This interview was recorded virtually.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Philip Murphy

1:28
Ongoing trials in multiple myeloma in Ireland
Philip Murphy • 1 Sep 2022
2:10
Highlights from IMS 2022
Philip Murphy • 1 Sep 2022
1:24
Treating patients with relapsed/refractory myeloma in Ireland
Philip Murphy • 1 Sep 2022
0:50
Challenges for HCPs in Ireland treating multiple myeloma
Philip Murphy • 1 Sep 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals